Base de dados : MEDLINE
Pesquisa : D04.210.500.925.100.125 [Categoria DeCS]
Referências encontradas : 495 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 50 ir para página                         

  1 / 495 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453908
[Au] Autor:Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
[Ad] Endereço:Endocrinology Unit, Maggiore-Bellaria Hospital, Medical Department, Azienda-Usl Bologna, Bologna, Italy.
[Ti] Título:Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
[So] Source:Andrology;5(4):671-678, 2017 07.
[Is] ISSN:2047-2927
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Despite their efficacy in the treatment of benign prostatic hyperplasia, the popularity of inhibitors of 5α-reductase (5ARIs) is limited by their association with adverse sexual side effects. The aim of this study was to review and meta-analyze currently available randomized clinical trials evaluating the rate of sexual side effects in men treated with 5ARIs. An extensive Medline Embase and Cochrane search was performed including the following words: 'finasteride', 'dutasteride', 'benign prostatic hyperplasia'. Only placebo-controlled randomized clinical trials evaluating the effect of 5ARI in subjects with benign prostatic hyperplasia were considered. Of 383 retrieved articles, 17 were included in this study. Randomized clinical trials enrolled 24,463 in the active and 22,270 patients in the placebo arms, respectively, with a mean follow-up of 99 weeks and mean age of 64.0 years. No difference was observed between trials using finasteride or dutasteride as the active arm considering age, trial duration, prostate volume or International Prostatic Symptoms Score at enrollment. Overall, 5ARIs determined an increased risk of hypoactive sexual desire [OR = 1.54 (1.29; 1.82); p < 0.0001] and erectile dysfunction [OR = 1.47 (1.29; 1.68); p < 0.0001]. No difference between finasteride and dutasteride regarding the risk of hypoactive sexual desire and erectile dysfunction was observed. Meta-regression analysis showed that the risk of hypoactive sexual desire and erectile dysfunction was higher in subjects with lower Q at enrollment and decreased as a function of trial follow-up. Conversely, no effect of age, low urinary tract symptom or prostate volume at enrollment as well as Q at end-point was observed. In conclusion, present data show that the use of 5ARI significantly increases the risk of erectile dysfunction and hypoactive sexual desire in subjects with benign prostatic hyperplasia. Patients should be adequately informed before 5ARIs are prescribed.
[Mh] Termos MeSH primário: Inibidores de 5-alfa Redutase/efeitos adversos
Dutasterida/efeitos adversos
Disfunção Erétil/induzido quimicamente
Finasterida/efeitos adversos
Hiperplasia Prostática/tratamento farmacológico
Disfunções Sexuais Psicogênicas/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Idoso
Disfunção Erétil/fisiopatologia
Seres Humanos
Libido/efeitos dos fármacos
Masculino
Meia-Idade
Ereção Peniana/efeitos dos fármacos
Hiperplasia Prostática/enzimologia
Ensaios Clínicos Controlados Aleatórios como Assunto
Fatores de Risco
Comportamento Sexual/efeitos dos fármacos
Disfunções Sexuais Psicogênicas/fisiopatologia
Disfunções Sexuais Psicogênicas/psicologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); 57GNO57U7G (Finasteride); O0J6XJN02I (Dutasteride)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1111/andr.12353


  2 / 495 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28982631
[Au] Autor:Litim N; Morissette M; Caruso D; Melcangi RC; Di Paolo T
[Ad] Endereço:Neuroscience Research Unit, Centre Hospitalier Universitaire de Québec, CHUL, Quebec City, Canada; Faculty of Pharmacy, Laval University, Quebec City, Canada.
[Ti] Título:Effect of the 5α-reductase enzyme inhibitor dutasteride in the brain of intact and parkinsonian mice.
[So] Source:J Steroid Biochem Mol Biol;174:242-256, 2017 Nov.
[Is] ISSN:1879-1220
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Dutasteride is a 5alpha-reductase inhibitor in clinical use to treat endocrine conditions. The present study investigated the neuroprotective mechanisms of action of dutasteride in intact and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mice using a low dose of MPTP not affecting motor activity modeling early stages of Parkinson's disease (PD). We hypothesized that dutasteride neuroprotection is due to altered steroids levels. Dutasteride pre-treatment prevented loss of striatal dopamine (DA) and its metabolite DOPAC. Dutasteride decreased effects of MPTP on striatal dopamine transporter (DAT), vesicular monoamine transporter 2 (VMAT2) and D2 DA receptor specific binding while D1 receptor specific binding remained unchanged. Dutasteride enhanced DAT specific binding and the glycosylated form of DAT in intact mice. MPTP-lesioned mice had plasma and brain testosterone and dihydrotestosterone levels lower than control mice whereas progesterone and its metabolites (dihydroprogesterone, isopregnanolone and tetrahydroprogesterone) pathway showed increases. Dutasteride treatment by inhibiting transformation of progesterone and testosterone to its metabolites elevated plasma and brain concentrations of testosterone compared to MPTP mice and decreased DHT levels in intact mice. Plasma and brain estradiol levels were low and remained unchanged by MPTP and/or dutasteride treatment. Dutasteride treatment did not affect striatal phosphorylation of Akt and its downstream substrate GSK3ß as well as phosphorylation of ERK1/2 in intact and MPTP lesioned MPTP mice. Striatal glial fibrillary acidic protein (GFAP) levels were markedly elevated in MPTP compared to control mice and dutasteride reduced GFAP levels in MPTP mice. Treatment with dutasteride post-lesion left unchanged striatal DA levels. These results suggest dutasteride as promising drug for PD neuroprotection.
[Mh] Termos MeSH primário: Inibidores de 5-alfa Redutase/farmacologia
Encéfalo/efeitos dos fármacos
Dutasterida/farmacologia
Intoxicação por MPTP/metabolismo
Fármacos Neuroprotetores/farmacologia
[Mh] Termos MeSH secundário: Inibidores de 5-alfa Redutase/uso terapêutico
Androgênios/sangue
Androgênios/metabolismo
Animais
Comportamento Animal/efeitos dos fármacos
Encéfalo/metabolismo
Dopamina/metabolismo
Proteínas da Membrana Plasmática de Transporte de Dopamina/genética
Proteínas da Membrana Plasmática de Transporte de Dopamina/metabolismo
Dutasterida/uso terapêutico
Proteína Glial Fibrilar Ácida/metabolismo
Intoxicação por MPTP/tratamento farmacológico
Intoxicação por MPTP/fisiopatologia
Masculino
Camundongos Endogâmicos C57BL
Fármacos Neuroprotetores/uso terapêutico
Desempenho Psicomotor/efeitos dos fármacos
Receptores de Dopamina D1/metabolismo
Receptores de Dopamina D2/metabolismo
Congêneres da Testosterona/sangue
Congêneres da Testosterona/metabolismo
Proteínas Vesiculares de Transporte de Monoamina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); 0 (Androgens); 0 (Dopamine Plasma Membrane Transport Proteins); 0 (Glial Fibrillary Acidic Protein); 0 (Neuroprotective Agents); 0 (Receptors, Dopamine D1); 0 (Receptors, Dopamine D2); 0 (Slc18a2 protein, mouse); 0 (Testosterone Congeners); 0 (Vesicular Monoamine Transport Proteins); 0 (glial fibrillary astrocytic protein, mouse); O0J6XJN02I (Dutasteride); VTD58H1Z2X (Dopamine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171007
[St] Status:MEDLINE


  3 / 495 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28952704
[Au] Autor:Vinarov AZ; Spivak LG; Mironov AV
[Ad] Endereço:I.M. Sechenov First MSMU of Minzdrav of Russia, Moscow, Russia.
[Ti] Título:[Combination therapy for benign prostatic hyperplasia in the light of clinical guidelines].
[So] Source:Urologiia;(4):120-128, 2017 Sep.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The article reviews clinical trials on the effectiveness of combination therapy with 5-reductase inhibitors and -blockers in men with benign prostatic hyperplasia (BPH). These trials have demonstrated a significant improvement in the symptoms and quality of life in this group of patients. The authors outline main strategies offered by the Russian clinical guidelines for BPH patients.
[Mh] Termos MeSH primário: Inibidores de 5-alfa Redutase/uso terapêutico
Antagonistas Adrenérgicos alfa/uso terapêutico
Dutasterida/uso terapêutico
Hiperplasia Prostática/tratamento farmacológico
Sulfonamidas/uso terapêutico
[Mh] Termos MeSH secundário: Combinação de Medicamentos
Seres Humanos
Masculino
Meia-Idade
Guias de Prática Clínica como Assunto
Hiperplasia Prostática/fisiopatologia
Hiperplasia Prostática/psicologia
Qualidade de Vida
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); 0 (Adrenergic alpha-Antagonists); 0 (Drug Combinations); 0 (Sulfonamides); G3P28OML5I (tamsulosin); O0J6XJN02I (Dutasteride)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE


  4 / 495 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28670847
[Au] Autor:Chen H; Na R; Packiam VT; Conran CA; Jiang D; Tao S; Yu H; Lin X; Meng W; Zheng SL; Brendler CB; Helfand BT; Xu J
[Ad] Endereço:Center for Genomic Translational Medicine and Prevention, School of Public Health, Fudan University, Shanghai, P. R. China.
[Ti] Título:Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.
[So] Source:Prostate;77(11):1179-1186, 2017 Aug.
[Is] ISSN:1097-0045
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Although the clinical validity of risk-associated single nucleotide polymorphisms (SNPs) for assessment of disease susceptibility has been consistently established, risk reclassification from increasing numbers of implicated risk-associated SNPs raises concern that it is premature for clinical use. Our objective is to assess the degree and impact of risk reclassification with the increasing number of SNPs. METHODS: A total of 3239 patients from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial were included. Four genetic risk scores (GRSs) were calculated based on sets of sequentially discovered prostate cancer (PCa) risk-associated SNPs (17, 34, 51, and 68 SNPs). RESULTS: Pair-wise correlation coefficients between sets of GRSs increased as more SNPs were included in the GRS: 0.80, 0.86, and 0.95 for 17 versus 34 SNPs, 34 versus 51 SNPs, and 51 versus 68 SNPs, respectively. Using a GRS of 1.5 as a cutoff for higher versus lower risk, reclassification rates of PCa risk decreased: 14.11%, 12.04%, and 8.15% for 17 versus 34 SNPs, 34 versus 51 SNPs, and 51 versus 68 SNPs, respectively. Evolving GRSs, nevertheless, provide a tool for further refining risk assessment. When all four sequential GRSs were considered, the detection rates of PCa for men whose GRSs were consistently <1.5, reclassified, and consistently ≥1.5 were 20.8%, 29.67%, and 39.26%, respectively (P = 1.12 × 10 ). In comparison, the detection rates of PCa in men with negative or positive family history were 23.75% and 31.78%, respectively. CONCLUSIONS: Risk assessment using currently available SNPs is justified. Multiple GRS values from evolving sets of SNPs provide a valuable tool for better refining risk.
[Mh] Termos MeSH primário: Inibidores de 5-alfa Redutase/uso terapêutico
Dutasterida/uso terapêutico
Polimorfismo de Nucleotídeo Único/genética
Neoplasias da Próstata/tratamento farmacológico
Neoplasias da Próstata/genética
[Mh] Termos MeSH secundário: Idoso
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); O0J6XJN02I (Dutasteride)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170704
[St] Status:MEDLINE
[do] DOI:10.1002/pros.23369


  5 / 495 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28394496
[Au] Autor:Lee HN; Lee YS; Han DH; Lee KS
[Ad] Endereço:Department of Urology, Seoul Seonam Hospital, Ewha Womans University, Seoul, Korea.
[Ti] Título:Change of Ultrasound Estimated Bladder Weight and Bladder Wall Thickness After Treatment of Bladder Outlet Obstruction With Dutasteride.
[So] Source:Low Urin Tract Symptoms;9(2):67-74, 2017 May.
[Is] ISSN:1757-5672
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To investigate the change of bladder wall hypertrophy to relieve bladder outlet obstruction (BOO) by treatment with 5α-reductase inhibitor. METHODS: Men who have BOO confirmed by urodynamic study (BOO index ≥40) were treated with dutasteride 0.5 mg once a day for 6 months. We measured ultrasound estimated bladder weight (UEBW), UEBW divided by body surface area (UEBW/BSA), and bladder wall thickness (BWT) before and after treatment. Changes in LUTS parameters were assessed by using the International Prostate Symptom Score, uroflowmetry, residual urine volume, prostate volume, serum prostate-specific antigen (PSA), and LUTS outcome scores (LOS). Correlation between the change of LUTS parameters and UEBW, UEBW/BSA, and BWT were evaluated. We assessed the changes of bladder wall hypertrophy according to the results of benefit, satisfaction, and willingness to continue (BSW) questionnaire. RESULTS: Thirty patients completed the 6-month study. The mean UEBW was 47.10 ± 7.79 g before and 50.07 ± 5.39 g after dutasteride treatment (P = 0.259). The mean UEBW/BSA was 26.47 ± 4.30 g/m before and 28.2 ± 3.53 g/m after treatment (P = 0.253), and there was no definite change in mean BWT after treatment (P = 0.301). Most LUTS parameters including LOS significantly improved. Increased BOO index value was related to decreased BWT (ρ = 0.361, P = 0.049). There was no definite change in mean UEBW, UEBW/BSA, and BWT according to the results of the BSW questionnaire. CONCLUSIONS: There was no change in UEBW, UEBW/BSA and BWT despite improving most clinical parameters suggesting BOO. The changes of bladder wall hypertrophy parameters still have limitations to directly reflect the relief of BOO.
[Mh] Termos MeSH primário: Inibidores de 5-alfa Redutase/uso terapêutico
Dutasterida/uso terapêutico
Obstrução do Colo da Bexiga Urinária/tratamento farmacológico
Bexiga Urinária/patologia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Seres Humanos
Sintomas do Trato Urinário Inferior/diagnóstico por imagem
Sintomas do Trato Urinário Inferior/tratamento farmacológico
Masculino
Meia-Idade
Tamanho do Órgão
Estudos Prospectivos
Hiperplasia Prostática/diagnóstico por imagem
Hiperplasia Prostática/cirurgia
Resultado do Tratamento
Ultrassonografia
Obstrução do Colo da Bexiga Urinária/diagnóstico por imagem
Obstrução do Colo da Bexiga Urinária/patologia
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); O0J6XJN02I (Dutasteride)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170411
[St] Status:MEDLINE
[do] DOI:10.1111/luts.12110


  6 / 495 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28319231
[Au] Autor:Welk B; McArthur E; Ordon M; Anderson KK; Hayward J; Dixon S
[Ad] Endereço:Department of Surgery, Western University, London, Ontario, Canada2Institute for Clinical Evaluative Sciences, London, Ontario, Canada3Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
[Ti] Título:Association of Suicidality and Depression With 5α-Reductase Inhibitors.
[So] Source:JAMA Intern Med;177(5):683-691, 2017 May 01.
[Is] ISSN:2168-6114
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: There have been concerns raised by patients and regulatory agencies regarding serious psychiatric adverse effects associated with 5α-reductase inhibitors. Objective: To determine if there is an increased risk of suicide, self-harm, or depression among older men starting a 5α-reductase inhibitor for prostatic enlargement. Design, Setting, and Participants: A population-based, retrospective, matched cohort study using linked administrative data for 93 197 men ages 66 years or older (median [IQR] age, 75 [70-80] years) in Ontario, Canada, who initiated a new prescription for a 5α-reductase inhibitor during the study period (2003 through 2013). Participants were matched (using a propensity score that included 44 of our 96 covariates that included medical comorbidities, medication usage, and health care system utilization) to an equal number of men not prescribed a 5α-reductase inhibitor. Exposures: Duration of finasteride or dutasteride usage. Main Outcomes and Measures: Suicide. Secondary outcomes were self-harm and depression. Results: Men who used 5α-reductase inhibitors were not at a significantly increased risk of suicide (HR, 0.88; 95% CI, 0.53-1.45). Risk of self-harm was significantly increased during the initial 18 months after 5α-reductase inhibitor initiation (HR, 1.88; 95% CI, 1.34-2.64), but not thereafter. Incident depression risk was elevated during the initial 18 months after 5α-reductase inhibitor initiation (HR, 1.94; 95% CI, 1.73-2.16), and continued to be elevated, but to a lesser degree, for the remainder of the follow-up period (HR, 1.22; 95% CI, 1.08-1.37). The absolute increases in the event rates for these 2 outcomes were 17 per 100 000 patient-years and 237 per 100 000 patient-years, respectively. The type of 5α-reductase inhibitor (finasteride or dutasteride) did not significantly modify the observed associations with suicide, self-harm, and depression. Conclusions and Relevance: In a large cohort of men ages 66 years or older, we did not demonstrate an increased risk of suicide associated with 5α-reductase inhibitor use. However, the risk of self-harm and depression were increased compared with unexposed men. This is in keeping with postmarketing experience and patient concerns, and discontinuation of the medication in these circ umstances may be appropriate.
[Mh] Termos MeSH primário: Inibidores de 5-alfa Redutase/uso terapêutico
Depressão/epidemiologia
Transtorno Depressivo/epidemiologia
Hiperplasia Prostática/tratamento farmacológico
Ideação Suicida
Suicídio/estatística & dados numéricos
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Estudos de Casos e Controles
Dutasterida/uso terapêutico
Finasterida/uso terapêutico
Seres Humanos
Masculino
Ontário/epidemiologia
Estudos Retrospectivos
Fatores de Risco
Comportamento Autodestrutivo/epidemiologia
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); 57GNO57U7G (Finasteride); O0J6XJN02I (Dutasteride)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170321
[St] Status:MEDLINE
[do] DOI:10.1001/jamainternmed.2017.0089


  7 / 495 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28145028
[Au] Autor:Shibata Y; Arai S; Miyazawa Y; Shuto T; Nomura M; Sekine Y; Koike H; Matsui H; Ito K; Suzuki K
[Ad] Endereço:Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan.
[Ti] Título:Effects of Steroidal Antiandrogen or 5-alpha-reductase Inhibitor on Prostate Tissue Hormone Content.
[So] Source:Prostate;77(6):672-680, 2017 May.
[Is] ISSN:1097-0045
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The effects of a steroidal antiandrogen (AA) and 5-alpha-reductase inhibitor (5ARI) on prostate tissue hormone content and metabolism are not fully elucidated. The objective of this study is to investigate the hormone content and metabolism of the prostate tissues of patients treated with AA or 5ARI using the ultra-sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. METHODS: Thirty-nine patients with benign prostatic hyperplasia (BPH) undergoing transurethral surgery were included. Serum and prostate tissue hormone and prostate tissue hormone metabolism analyses were performed using LC-MS/MS after 1 month of treatment with chlormadinone acetate (CMA; steroidal AA, 50 mg/day) or dutasteride (DUTA; dual 5ARI, 0.5 mg/day). RESULTS: Serum testosterone (T), dihydrotestosterone (DHT), and adrenal androgen levels were lower in the CMA group than the control group. Prostate tissue T and DHT levels were also lower in the CMA group than the control group. In the DUTA group, only serum and prostate DHT concentrations were reduced compared to the control group; in contrast, those of other hormones, especially T and 4-androstene-3,17-dione in the prostate tissue, showed marked elevations up to 70.4- and 11.4-fold normal levels, respectively. Moreover, the hormone metabolism assay confirmed that the conversion of T to DHT was significantly suppressed while that of T to 4-androstene-3,17-dione was significantly accelerated in the prostate tissue of DUTA-treated patients. CONCLUSIONS: Although treatment with AA and 5ARI show similar clinical outcomes, their effect on tissue hormone content and metabolism varied greatly. Prostate 77: 672-680, 2017. © 2017 Wiley Periodicals, Inc.
[Mh] Termos MeSH primário: Inibidores de 5-alfa Redutase/uso terapêutico
Antagonistas de Androgênios/uso terapêutico
Próstata/efeitos dos fármacos
Próstata/metabolismo
Hiperplasia Prostática/tratamento farmacológico
Hiperplasia Prostática/metabolismo
[Mh] Termos MeSH secundário: Inibidores de 5-alfa Redutase/farmacologia
Idoso
Idoso de 80 Anos ou mais
Antagonistas de Androgênios/farmacologia
Acetato de Clormadinona/farmacologia
Acetato de Clormadinona/uso terapêutico
Dutasterida/farmacologia
Dutasterida/uso terapêutico
Seres Humanos
Masculino
Meia-Idade
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); 0 (Androgen Antagonists); 0SY050L61N (Chlormadinone Acetate); O0J6XJN02I (Dutasteride)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170810
[Lr] Data última revisão:
170810
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170202
[St] Status:MEDLINE
[do] DOI:10.1002/pros.23315


  8 / 495 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27644229
[Au] Autor:Milonas D; Auskalnis S; Skulcius G; Gudinaviciene I; Jievaltas M; Joniau S
[Ad] Endereço:Department of Urology, Lithuanian Health Science University, Eiveniu 2, 50009, Kaunas, Lithuania. daimantas.milonas@kaunoklinikos.lt.
[Ti] Título:Dutasteride for the prevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia: results of a phase III randomized open-label 3-year trial.
[So] Source:World J Urol;35(5):721-728, 2017 May.
[Is] ISSN:1433-8726
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: High-grade prostatic intraepithelial neoplasia (HGPIN) is a potential precursor of prostate cancer (PCa), and patients with HGPIN are at high risk for PCa development. Objective of our study was to evaluate the efficacy of dutasteride 0.5 mg in PCa prevention among men with isolated HGPIN on biopsy. METHODS: This prospective, randomized, phase III, open-label 3-year trial assessed dutasteride versus active surveillance in patients with HGPIN. Patients were randomized to dutasteride 0.5 mg daily or active surveillance. Per-protocol prostate biopsies were performed at 6, 12, 24, and 36 months until cancer detection or study end. The primary end point was cancer-free survival (CFS). An intention-to-treat analysis was done for patients who underwent at least one per-protocol biopsy. An efficacy analysis was done for patients who completed the study. CFS was evaluated using Kaplan-Meier and log-rank analysis. RESULTS: In total, 220 men were randomized (dutasteride, n = 107; surveillance, n = 113). PCa was detected in 47.6: 49.1 % in the surveillance group and 45.9 % in the treatment group (p = 0.66). The detected PCa differentiation by Gleason score (GS) was GS 6 in 76.9 %, GS 7 in 19.8 %, and GS ≥ 8 in 3.3 %, with no difference between groups. The 3-year PCa-free survival was 43.6 % in the surveillance and 49.6 % in the dutasteride group (log rank p = 0.57). Limitations include a relatively high non-adherence rate, open-label design, and baseline sextant biopsy scheme. CONCLUSIONS: Dutasteride 0.5 mg for 3 years did not lower the PCa detection rate but did not worsen detected PCa characteristics in men with HGPIN.
[Mh] Termos MeSH primário: Inibidores de 5-alfa Redutase/uso terapêutico
Carcinoma/prevenção & controle
Dutasterida/uso terapêutico
Neoplasia Prostática Intraepitelial/tratamento farmacológico
Neoplasias da Próstata/prevenção & controle
[Mh] Termos MeSH secundário: Idoso
Biópsia
Carcinoma/patologia
Seres Humanos
Masculino
Meia-Idade
Gradação de Tumores
Neoplasia Prostática Intraepitelial/patologia
Neoplasias da Próstata/tratamento farmacológico
Neoplasias da Próstata/patologia
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); O0J6XJN02I (Dutasteride)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160921
[St] Status:MEDLINE
[do] DOI:10.1007/s00345-016-1938-8


  9 / 495 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27549867
[Au] Autor:Shanshanwal SJ; Dhurat RS
[Ad] Endereço:Department of Dermatology, LTMMC and Lokmanya Tilak Municipal General Hospital, Mumbai, Maharashtra, India.
[Ti] Título:Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study.
[So] Source:Indian J Dermatol Venereol Leprol;83(1):47-54, 2017 Jan-Feb.
[Is] ISSN:0973-3922
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Finasteride and dutasteride are inhibitors of the enzyme 5-alpha-reductase which inhibits the conversion of testosterone to dihydrotestosterone. Dutasteride inhibits both type I and type II 5-alpha-reductase while finasteride inhibits only the type II enzyme. As both isoenzymes are present in hair follicles, it is likely that dutasteride is more effective than finasteride. AIMS: To compare the efficacy, safety and tolerability of dutasteride and finasteride in men with androgenetic alopecia. METHODS: Men with androgenetic alopecia between 18 and 40 years of age were randomized to receive 0.5 mg dutasteride or 1 mg finasteride daily for 24 weeks. The primary efficacy variables were hair counts (thick and thin) in the target area from modified phototrichograms and global photography evaluation by blinded and non-blinded investigators. The secondary efficacy variable was subjective assessment using a preset questionnaire. Patients were assessed monthly for side effects. RESULTS: Ninety men with androgenetic alopecia were recruited. The increase in total hair count per cm[2] representing new growth was significantly higher in dutasteride group (baseline- 223 hair; at 24 weeks- 246 hair) compared to finasteride group (baseline- 227 hair; at 24 weeks- 231 hair). The decrease in thin hair count per cm[2] suggestive of reversal of miniaturization was significantly higher in dutasteride group (baseline- 65 hair; at 24 weeks- 57 hair) compared to finasteride group (baseline- 67 hair; at 24 weeks- 66 hair). Both the groups showed a similar side effect profile with sexual dysfunction being the most common and reversible side effect. LIMITATIONS: Limitations include the short duration of the study (6 months), the small sample size and the fact that it was an open-label study. CONCLUSIONS: Dutasteride was shown to be more efficacious than finasteride and the side-effect profiles were comparable.
[Mh] Termos MeSH primário: Alopecia/diagnóstico
Alopecia/tratamento farmacológico
Dutasterida/administração & dosagem
Finasterida/administração & dosagem
Cabelo/efeitos dos fármacos
Cabelo/crescimento & desenvolvimento
[Mh] Termos MeSH secundário: Inibidores de 5-alfa Redutase/administração & dosagem
Inibidores de 5-alfa Redutase/efeitos adversos
Administração Oral
Adolescente
Adulto
Dutasterida/efeitos adversos
Disfunção Erétil/induzido quimicamente
Finasterida/efeitos adversos
Seres Humanos
Masculino
Estudos Prospectivos
Método Simples-Cego
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); 57GNO57U7G (Finasteride); O0J6XJN02I (Dutasteride)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170523
[Lr] Data última revisão:
170523
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160824
[St] Status:MEDLINE
[do] DOI:10.4103/0378-6323.188652


  10 / 495 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27461546
[Au] Autor:Fanton LE; Macedo CG; Torres-Chávez KE; Fischer L; Tambeli CH
[Ad] Endereço:Department of Physiology, Piracicaba Dental School, State University of Campinas - UNICAMP, Piracicaba, São Paulo, Brazil.
[Ti] Título:Activational action of testosterone on androgen receptors protects males preventing temporomandibular joint pain.
[So] Source:Pharmacol Biochem Behav;152:30-35, 2017 Jan.
[Is] ISSN:1873-5177
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Testosterone protects male rats from Temporomandibular Joint (TMJ) pain. This study investigated whether this protective effect is mediated by an organizational action of testosterone during nervous system development, by central estrogen and androgen receptors and by the 5α-reduced metabolite of testosterone, dihydrotestosterone. METHODS: A pharmacological approach was used to assess the ability of the androgen receptor antagonist flutamide, the estrogen receptor antagonist ICI 182 780 and the 5-α reductase inhibitor dutasteride to block the protective effect of testosterone, evaluated through the behavioral response induced by a TMJ injection of 0.5% formalin. Flutamide and ICI 182 780 were injected into the medullary subarachnoid space, and dutasteride and testosterone were systemically administered. RESULTS: The TMJ injection of 0.5% formalin induced a significant nociceptive behavioral response in gonadectomized male and naïve female, but not in sham gonadectomized male rats, confirming that endogenous testosterone prevents TMJ nociception in males. Testosterone administration prevented formalin-induced TMJ nociception in males gonadectomized either in the neonatal (at the day of birth) or adult period and in naïve female rats, suggesting that the protective effect of testosterone on TMJ nociception does not depend on its organizational actions during critical periods of development. The administration of flutamide and dutasteride but not of ICI 182 780 blocked the protective effect of testosterone. CONCLUSIONS: We conclude that the protective effect of testosterone on TMJ nociception depends on activational actions of dihydrotestosterone on androgen receptors rather than on organizational androgenic actions during central nervous system development or estrogenic actions.
[Mh] Termos MeSH primário: Inibidores de 5-alfa Redutase/farmacologia
Antagonistas de Androgênios/farmacologia
Medição da Dor/efeitos dos fármacos
Dor/prevenção & controle
Receptores Androgênicos/metabolismo
Articulação Temporomandibular/efeitos dos fármacos
Testosterona/farmacologia
[Mh] Termos MeSH secundário: Animais
Dutasterida/farmacologia
Estradiol/análogos & derivados
Estradiol/farmacologia
Antagonistas do Receptor de Estrogênio/farmacologia
Feminino
Flutamida/farmacologia
Formaldeído
Masculino
Ratos
Articulação Temporomandibular/fisiopatologia
Testosterona/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); 0 (Androgen Antagonists); 0 (Estrogen Receptor Antagonists); 0 (Receptors, Androgen); 1HG84L3525 (Formaldehyde); 22X328QOC4 (fulvestrant); 3XMK78S47O (Testosterone); 4TI98Z838E (Estradiol); 76W6J0943E (Flutamide); O0J6XJN02I (Dutasteride)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170601
[Lr] Data última revisão:
170601
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160728
[St] Status:MEDLINE



página 1 de 50 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde